Filing Flows

Filing Flows › Companies › InfuSystem Holdings › Cash flow

InfuSystem Holdings cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow$6.7M in Q2 2026 · $22.9M over twelve months

Operating cash flow$6.8M
Capital spending−$91K
Free cash flow+$6.7M
Cash / net income2.1×
Cash conversion cycle42 days

Analysis

In Q2 2026, InfuSystem Holdings generated $6.8M of operating cash flow and spent $91K on capital projects, leaving free cash flow of $6.7M. That is $106K less than in Q2 2025 ($6.8M).

Over the twelve months to Jun 30, 2026, operating cash flow was $23.4M; the largest uses were net borrowing (+) / repaid (−) ($35.0M), other investing ($10.4M), buybacks ($7.8M); besides operations, cash came from other financing ($29.0M), asset & business sales ($2.6M); the cash balance rose by $244K.

Operating cash flow was $6.8M against net income of $3.2M — 2.1× profit, cash ran ahead of reported earnings. The largest differences: receivables −$3.4M, depreciation & amortization +$3.2M, stock-based pay +$1.2M.

Its cash conversion cycle was 42 days (receivables 63 + inventory 33 − payables 55).

Free cash flow

InfuSystem Holdings: free cash flow by quarterInfuSystem Holdings: free cash flow by quarter$9.8MQ3 2024$7.4MQ4 2024$1.6MQ1 2025$6.8MQ2 2025$8.4MQ3 2025$7.0MQ4 2025$813KQ1 2026$6.7MQ2 2026
Operating cash flow less capital spending.
InfuSystem Holdings: operating cash flow against capital spendingInfuSystem Holdings: operating cash flow against capital spendingOperating cash flowCapital spending$9.8M$43KQ3 2024$7.9M$530KQ4 2024$1.8M$131KQ1 2025$7.0M$217KQ2 2025$8.5M$79KQ3 2025$7.1M$133KQ4 2025$970K$157KQ1 2026$6.8M$91KQ2 2026
Latest (Q2 2026): Operating cash flow $6.8M, Capital spending $91K.

Capital allocation, year by year

InfuSystem Holdings: where the cash came from (up) and went (down), by fiscal yearInfuSystem Holdings: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingAcquisitionsBuybacksFY2021: Operating cash flow $18.3MFY2021: Net borrowing −$81.7MFY2021: Shares issued $1.1MFY2021: Asset sales $3.3MFY2021: Capital spending −$980KFY2021: Acquisitions −$7.7MFY2021: Buybacks −$560K$22.8MFY2021FY2022: Operating cash flow $17.5MFY2022: Net borrowing −$42.0MFY2022: Shares issued $1.4MFY2022: Asset sales $3.6MFY2022: Capital spending −$982KFY2022: Buybacks −$5.5M$22.5MFY2022FY2023: Operating cash flow $11.2MFY2023: Net borrowing −$55.5MFY2023: Shares issued $1.1MFY2023: Asset sales $4.4MFY2023: Capital spending −$1.0MFY2023: Buybacks −$153K$16.7MFY2023FY2024: Operating cash flow $20.5MFY2024: Net borrowing −$56.1MFY2024: Shares issued $387KFY2024: Asset sales $4.6MFY2024: Capital spending −$1.1MFY2024: Buybacks −$1.2M$25.4MFY2024FY2025: Operating cash flow $24.4MFY2025: Net borrowing −$52.3MFY2025: Shares issued $335KFY2025: Asset sales $3.3MFY2025: Capital spending −$560KFY2025: Acquisitions −$1.4MFY2025: Buybacks −$9.9M$28.1MFY2025
Over these 5 years operating cash flow totalled $91.9M; the largest uses were net borrowing ($288M) and buybacks ($17.2M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$964K
Debt$20.4M
Net debt$19.5M

InfuSystem Holdings funds itself: free cash flow was $22.9M over the last twelve months, and $964K of cash and investments stands against $20.4M of debt.

Where the cash came from and went

InfuSystem Holdings: sources (+) and uses (−) of cash, Q2 2026InfuSystem Holdings: sources (+) and uses (−) of cash, Q2 2026Other financing$7.5MOperating cash flow$6.8MNet borrowing (+) / repaid (−)−$6.7MOther investing−$4.9MBuybacks−$3.5MCash drawn (+) / kept (−)$1.1MTaxes on employees’ shares−$610KAsset & business sales$431KCapital spending−$91KShares issued$5K
InfuSystem Holdings: sources (+) and uses (−) of cash, TTM to Q2 2026InfuSystem Holdings: sources (+) and uses (−) of cash, TTM to Q2 2026Net borrowing (+) / repaid (−)−$35.0MOther financing$29.0MOperating cash flow$23.4MOther investing−$10.4MBuybacks−$7.8MAsset & business sales$2.6MTaxes on employees’ shares−$1.4MCapital spending−$460KShares issued$365KCash drawn (+) / kept (−)−$244K

From profit to cash

InfuSystem Holdings: net income to operating cash flow, Q2 2026InfuSystem Holdings: net income to operating cash flow, Q2 2026Net income$3.2MDepreciation & amortization$3.2MStock-based pay$1.2MDeferred taxes$640KGains on disposals−$219KReceivables−$3.4MInventory$796KPayables$725KPrepaid and other assets$87KOperating cash flow$6.8M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 202663335542
Q1 202663366633
Q4 202560326131
Q3 202562335738
Q2 202561335044
Q1 202558375342
Q4 202460395543
Q3 202457385342

Every quarter

QuarterOperating cash flowCapital spendingBuybacksNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026$6.8M−$91K−$3.5M−$6.7M$5K$1.1M$6.7M
Q1 2026$970K−$157K−$809K−$6.1M$184K$1.1M$813K
Q4 2025$7.1M−$133K−$1.3M−$8.1M−$1K−$2.2M$7.0M
Q3 2025$8.5M−$79K−$2.2M−$14.0M$177K−$235K$8.4M
Q2 2025$7.0M−$217K−$3.5M−$15.9M—$786K$6.8M
Q1 2025$1.8M−$131K−$2.9M−$14.4M$159K−$979K$1.6M
Q4 2024$7.9M−$530K−$199K−$15.7M$6K−$147K$7.4M
Q3 2024$9.8M−$43K−$698K−$13.7M$156K−$234K$9.8M

InfuSystem Holdings: income statement and cash flow

InfuSystem Holdings, Q3 2026: revenue $37.6M (+3% year over year), operating margin 12.6%. The chart follows the revenue to costs, profit and cash.

InfuSystem Holdings: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.